Source link : https://www.newshealth.biz/health-news/eu-regulator-rejects-alzheimers-drug-lecanemab/
Getty Images The European Medicines Agency (EMA) has rejected a licence for an Alzheimer’s treatment which slows cognitive decline. The EMA said the benefits of lecanemab did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain. The medicines regulator in the UK, the MHRA, is still considering whether to […]
Author : News Health
Publish date : 2024-07-26 17:01:49
Copyright for syndicated content belongs to the linked Source.
Categories